Publications by authors named "Constantine Balotis"
Article Synopsis
- Posttransplant lymphoproliferative disorder (PTLD) is a rare but serious complication in solid organ transplant patients, and chemotherapy can lead to significant side effects.
- The TIDaL trial tested the safety and effectiveness of ibrutinib, alongside a risk-based treatment strategy, for newly diagnosed patients with CD20+ B-cell PTLD.
- While ibrutinib did not meet the effectiveness threshold anticipated, the study highlighted the potential to reduce exposure to harsher chemotherapy treatments for patients in the low-risk category, indicating a direction for future research.
Delayed lymphocyte and T-cell immune reconstitution following bendamustine-rituximab (BR) for indolent non-Hodgkin lymphoma (iNHL) has been described, but no information is available for chronic lymphocytic leukaemia (CLL). We present a population-based retrospective analysis of immune reconstitution and risk of infection following BR. Outcomes included timing/correlates of CD4+ recovery and risk of ≥grade 3 infections.
View Article and Find Full Text PDFCUDC-907, a dual PI3K/HDAC inhibitor, has been proposed to have therapeutic potential in hematopoietic malignancies. However, the molecular mechanisms of its effects in chronic lymphocytic leukaemia (CLL) remain elusive. We show that CLL cells are sensitive to CUDC-907, even under conditions similar to the protective microenvironment of proliferation centres.
View Article and Find Full Text PDF